Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

353 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia not adequately controlled with current lipid-lowering therapy: design and rationale of the ODYSSEY FH studies.
Kastelein JJ, Robinson JG, Farnier M, Krempf M, Langslet G, Lorenzato C, Gipe DA, Baccara-Dinet MT. Kastelein JJ, et al. Among authors: robinson jg. Cardiovasc Drugs Ther. 2014 Jun;28(3):281-9. doi: 10.1007/s10557-014-6523-z. Cardiovasc Drugs Ther. 2014. PMID: 24842558 Free PMC article. Clinical Trial.
Pharmacodynamic relationship between PCSK9, alirocumab, and LDL-C lowering in the ODYSSEY CHOICE I trial.
Roth EM, Kastelein JJP, Cannon CP, Farnier M, McKenney JM, DiCioccio AT, Brunet A, Manvelian G, Sasiela WJ, Baccara-Dinet MT, Zhao J, Robinson JG. Roth EM, et al. Among authors: robinson jg. J Clin Lipidol. 2020 Sep-Oct;14(5):707-719. doi: 10.1016/j.jacl.2020.07.009. Epub 2020 Jul 25. J Clin Lipidol. 2020. PMID: 32928709 Free article. Clinical Trial.
Efficacy and safety of alirocumab, a fully human PCSK9 monoclonal antibody, in high cardiovascular risk patients with poorly controlled hypercholesterolemia on maximally tolerated doses of statins: rationale and design of the ODYSSEY COMBO I and II trials.
Colhoun HM, Robinson JG, Farnier M, Cariou B, Blom D, Kereiakes DJ, Lorenzato C, Pordy R, Chaudhari U. Colhoun HM, et al. Among authors: robinson jg. BMC Cardiovasc Disord. 2014 Sep 20;14:121. doi: 10.1186/1471-2261-14-121. BMC Cardiovasc Disord. 2014. PMID: 25240705 Free PMC article. Clinical Trial.
PCSK9 Inhibitors and Cardiovascular Events.
Robinson JG, Kastelein JJ. Robinson JG, et al. N Engl J Med. 2015 Aug 20;373(8):774. doi: 10.1056/NEJMc1508222. N Engl J Med. 2015. PMID: 26287854 No abstract available.
No effect of PCSK9 inhibitor alirocumab on the incidence of diabetes in a pooled analysis from 10 ODYSSEY Phase 3 studies.
Colhoun HM, Ginsberg HN, Robinson JG, Leiter LA, Müller-Wieland D, Henry RR, Cariou B, Baccara-Dinet MT, Pordy R, Merlet L, Eckel RH. Colhoun HM, et al. Among authors: robinson jg. Eur Heart J. 2016 Oct 14;37(39):2981-2989. doi: 10.1093/eurheartj/ehw292. Epub 2016 Jul 26. Eur Heart J. 2016. PMID: 27460890 Free PMC article. Clinical Trial.
Long-term treatment adherence to the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab in 6 ODYSSEY Phase III clinical studies with treatment duration of 1 to 2 years.
Farnier M, Colhoun HM, Sasiela WJ, Edelberg JM, Asset G, Robinson JG. Farnier M, et al. Among authors: robinson jg. J Clin Lipidol. 2017 Jul-Aug;11(4):986-997. doi: 10.1016/j.jacl.2017.05.016. Epub 2017 Jun 8. J Clin Lipidol. 2017. PMID: 28693998 Free article. Clinical Trial.
353 results